May 9, 2019
Takeda sells Xiidra to Novartis for up to $5.3B, TachoSil to Ethicon for $400M
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
May 9, 2019
Bicycle Therapeutics adds two senior figures to clinical team to advance expanding pipeline
Bicycle Therapeutics today announced two senior appointments to facilitateits expanding and advancing clinical pipeline.
May 9, 2019
Promethera doses patients with HepaStem testing drug for Liver Stem Cell Therapy in Late-Stage NASH
Promethera doses patients with HepaStem drug testing it in late stage non-alcoholic steatohepatitis
May 9, 2019
‘A Vision for Lupus’ Report, Published Ahead of World Lupus Day, Highlights an Important Need to Improve Quality of Care for Lupus Patients
Systemic Lupus Erythematosus (SLE), also known as lupus, is a chronic,inflammatory, autoimmune disease affecting 5 million people worldwidewith 70%-90% of these cases appearing in females
May 6, 2019
GenSight Biologics to present Data from the Reverse Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)
GenSIght will present results from the REVERSE Phase III clinical trial of GS010 at the 2019 American Academy of Neurology (AAN) Annual Meeting
May 5, 2019
UroGen Phase 3 OLYMPUS Trial shows UGN-101 as an initial kidney-sparing treatment option for low-gradeUTUC
59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).
May 3, 2019
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company,announced that on May 3, 2019 the Compensation Committee of Puma’s Boardof Directors approved the grant of inducement restricted stock unitawards covering an aggregate of 49,125 shares of Puma common stock tonine new non-executive employees.
May 3, 2019
Dicerna approves purchase of 145,500 shares of common stock to bedistributed among eight new employees
Dicerna Pharmaceuticals Board of Directors approved the grant of inducement stockoptions to purchase a total of 145,500 shares of common stock to bedistributed among eight new employees
May 3, 2019
FDA Approves Genentech’s Kadcyla for Adjuvant Treatment HER2-Positive Early Breast Cancer
Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer
May 3, 2019
Seattle Genetics expands Adcetris indications in Canada
Health Canada hasapproved the supplemental New Drug Submission that expands the use ofADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin,vinblastine and dacarbazine) chemotherapy in patients with previouslyuntreated Stage IV Hodgkin lymphoma (HL).